Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;64(11):1730-8.
doi: 10.1002/acr.21807.

Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia

Affiliations

Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia

Kristin Palmsten et al. Arthritis Care Res (Hoboken). 2012 Nov.

Abstract

Objective: To describe patterns of disease-modifying antirheumatic drug (DMARD) use during pregnancy in a population-based cohort, and to evaluate the association between autoimmune disease, DMARDs, corticosteroids, and nonsteroidal antiinflammatory drugs (NSAIDs) and preeclampsia.

Methods: Using health care utilization databases from British Columbia (1997-2006), we compared the risk for preeclampsia among 44,786 women with and without autoimmune disease with study drug dispensings before pregnancy (past users) and before and during the first 20 gestational weeks (continuous users). Relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated.

Results: Only 414 women (0.1%) had a DMARD dispensing during pregnancy. The incidence of preeclampsia was 2.3% for past DMARD users, 2.7% for past corticosteroid users, and 2.9% for past NSAID users. Compared to past users, the continuous DMARD user RR was 2.29 (95% CI 0.81-6.44), and was 0.89 (95% CI 0.51-1.56) for corticosteroid and 0.84 (95% CI 0.63-1.10) for NSAID users. Compared to women without autoimmune disease, the delivery year-adjusted RR was 2.02 (95% CI 1.11-3.64) for women with systemic lupus erythematosus (SLE). The DMARD results were attenuated when antimalarials were excluded, and the delivery year-adjusted RR was 0.95 (95% CI 0.25-3.55) when the DMARD analysis was restricted to women with autoimmune disease.

Conclusion: Few women were exposed to DMARDs during pregnancy. We observed a 2-fold increased risk of preeclampsia among women with SLE and a nonsignificant increase in risk in DMARD users. The DMARD and preeclampsia association was attenuated when antimalarials were excluded and null when restricted to women with autoimmune disease, which suggests the association is likely due to greater autoimmune disease severity in DMARD users.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest: The Pharmacoepidemiology Program at the Harvard School of Public Health receives funding from Pfizer and Asisa. Dr. Setoguchi received honoraria from Sanofi-Aventis and research support from Johnson and Johnson. Dr. Hernández-Díaz has consulted for AstraZeneca, Novartis, and GlaxoSmithKline Biologicals. Dr. Solomon has received research support from Abbott, Amgen, and Lilly.

Figures

Figure 1
Figure 1
Study timeline. LMP, last menstrual period.
Figure 2
Figure 2
Pre-pregnancy and pregnancy DMARD use among 306,831 pregnancies identified from the British Columbia healthcare utilization databases between 1997–2006. LMP, last menstrual period; DMARD, Disease-Modifying Antirheumatic Drug.

Similar articles

Cited by

References

    1. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension. 2003;41(3):437–45. - PubMed
    1. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Pregnancy complications and delivery practice in women with connective tissue disease and inflammatory rheumatic disease in Norway. Acta Obstet Gynecol Scand. 2000;79(6):490–5. - PubMed
    1. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54(3):899–907. - PubMed
    1. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199(2):127 e121–6. - PMC - PubMed
    1. Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet Gynecol. 2004;103(6):1190–3. - PubMed

Publication types

MeSH terms

Substances